RT Journal Article
SR Electronic
T1 Early Treatment with Hydroxychloroquine and Azithromycin: A ‘Real-World’ Monocentric Retrospective Cohort Study of 30,423 COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.03.23287649
DO 10.1101/2023.04.03.23287649
A1 Million, Matthieu
A1 Cortaredona, Sébastien
A1 Delorme, Léa
A1 Colson, Philippe
A1 Levasseur, Anthony
A1 Tissot-Dupont, Hervé
A1 Cassir, Nadim
A1 Bendamardji, Karim
A1 Lahouel, Salima
A1 Scola, Bernard La
A1 Camoin-Jau, Laurence
A1 Fenollar, Florence
A1 Gautret, Philippe
A1 Parola, Philippe
A1 Lagier, Jean-Christophe
A1 Gentile, Stéphanie
A1 BRouqui, Philippe
A1 Raoult, Didier
YR 2023
UL http://medrxiv.org/content/early/2023/06/07/2023.04.03.23287649.abstract
AB The authors have withdrawn this manuscript because analytic strategies for this project have changed. Therefore, the authors do not wish this work to be cited as reference for the project.Competing Interest StatementAll authors have completed the Unified Competing Interest form (available on request from the corresponding author). DR declare grants or contracts and royalties or licenses from Hitachi High-Technologies Corporation, Tokyo, Japan. DR is scientific board member of Eurofins company. DR is founder and shareholder of a microbial culture company (Culture Top), two biotechnology companies (Techno-jouvence, and Gene and Green TK), and a rapid diagnosis of infectious diseases company (Pocrame). All authors declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years, no other relationships or activities that could appear to have influenced the submitted work. Our group used widely available generic drugs distributed by many pharmaceutical companies.Funding StatementThis work was performed by academic doctors working in the IHU Mediterranee Infection. IHU Mediterranee Infection was funded by the French government and benefited from a grant from Agence Nationale de la Recherche: ANR-15-CE36-0004-01 and by ANR Investissements d avenir, Mediterranee infection 10-IAHU-03, and was also supported by Region Provence-Alpes-Cote d Azur.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical committee of the Institut Hospitalo-Universitaire Mediterranee Infection gave ethical approval for this work (N: 2021-007 for outpatients and 2021-015 for inpatients).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes